AlphAIAlphAI — Financial news for AI agents
uk.investing.com$ANGO

Earnings call transcript: AngioDynamics beats Q1 2026 forecasts as shares fall premarket

AngioDynamics reported a narrower-than-expected Q1 2027 loss of $0.04 per share, beating estimates of $0.11. Revenue rose 6.9% to $80.9M, slightly above forecasts. Shares fell 2.96% premarket. Med Tech revenue grew 13.2%, now 49% of total sales. Full-year guidance remained unchanged, with revenue expected between $336M and $341M.

Original reporting
uk.investing.com
Published Oct 8, 2026, 12:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 1:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ANGO
Bearish
high confidence
Mentioned
$ANGO
Relevance
7/10
AlphAI data visualization · based on uk.investing.com
Decision brief

The 30-second read

$ANGOBearishMed
01

Why it matters

The earnings beat was narrow and guidance unchanged, leading to a pre‑market sell‑off as investors weigh cash burn versus margin improvement.

02

Market read

First‑time earnings release for AngioDynamics; modest impact on broader market but relevant for med‑tech investors.

03

What to watch

Tariff refunds boosted gross margin; continued reimbursement progress for NanoKnife could improve cash flow later in the year.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

AngioDynamics is transitioning from traditional medical devices to higher‑growth MedTech products.

Company-level read

Ticker impact

$ANGOBearishHigh confidence
Context

AngioDynamics reported Q1 2026 earnings beating loss expectations but shares fell 2.96% pre‑market.

Expected impact

modest downside as market prices in unchanged guidance and cash outflow concerns

Evidence & confidence

The earnings beat was modest and revenue beat minimal; investors focused on full‑year outlook and cash burn, driving the pre‑market decline.

Market effects

Sector

MedTech segment shows stronger growth, may boost peer valuations in the medical device space.

Regional

U.S. small‑cap medical device stocks could see slight pressure as investors reassess cash usage.

Global

Limited; impact confined to U.S. med‑tech equities.

Counterpoint

What could challenge this read

Despite the share drop, the earnings beat and margin expansion could support a short‑term bounce.

Key entities

  • Executive
    Jim Clemmer

    CEO who highlighted the 21st straight quarter of double‑digit growth.

  • Executive
    Steve Trowbridge

    CFO who explained gross‑margin drivers and outlook.

Read at source← All news

StoryAngioDynamics posts Q1 FY2027 earnings beat and names new CEO

Also covered by

4 outlets

Related articles

$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife IRE for Prostate and Liver Cancer

AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.

marketscreener.com
$ANGOMed

H.C. Wainwright cuts AngioDynamics stock price target to $18

H.C. Wainwright reduced its price target for AngioDynamics (ANGO) to $18 from $19, maintaining a Buy rating. The company reported fiscal Q1 2027 net sales of $80.9M, up 6.9% YoY, but a net loss of $7.1M. Guidance for fiscal 2027 includes revenue of $336M-$341M and adjusted EBITDA of $13M-$16M. Canaccord Genuity reiterated its Buy rating with a $20 target, citing growth in key platforms. The stock fell 23% post-earnings.

investing.com
$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Polic

AngioDynamics (ANGO) announced Humana's updated Medicare Advantage coverage policy for its NanoKnife System, effective October 1, 2026. The policy applies LCD L40205 criteria for IRE technology, covering eligible patients with intermediate-risk prostate cancer and certain liver tumors. This follows recent reimbursement milestones, including CPT codes and Palmetto GBA's LCD. Humana, with 7 million members, will use LCD L40205 criteria for consistent coverage.

gurufocus.com
$ANGOHigh

AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics (ANGO) reported Q1 2027 revenue growth of 7%, with the MedTech segment up 13%. Auryon saw 14.7% growth, marking 21 consecutive quarters of double-digit gains. AlphaVac revenue rose 37.4% year-over-year. The company named Eric Honer as its new CEO, effective November 2. NanoKnife received FDA approval for a BPH study, targeting a $1.9B market. Med Device segment grew 1.4%.

finance.yahoo.com